Comparison of Pain Levels in Fusion Prostate Biopsy and Standard TRUS-Guided Biopsy

Sponsor
TC Erciyes University (Other)
Overall Status
Completed
CT.gov ID
NCT03859804
Collaborator
(none)
252
1
2
26
9.7

Study Details

Study Description

Brief Summary

The aim of this study was to compare the pain levels in transrectal ultrasound (TRUS)-guided standard 12-core prostate biopsy (SPB) and multiparametric prostate magnetic resonance imaging (MpMRI)-guided fusion prostate biopsy (FPB).

Condition or Disease Intervention/Treatment Phase
  • Procedure: Standard transrectal 12 core biopsy
  • Procedure: MRI- US fusion prostate biopsy (FPB)
N/A

Detailed Description

The study included patients that underwent prostate biopsy under local anesthesia (intrarectal 2% lidocaine gel + periprostatic nerve block) due to suspected prostate cancer. Patients detected with a Prostate Imaging Reporting and Data System score (PIRADS) ≥3 lesion on MpMRI underwent MpMRI-guided FPB (Group I) and the patients who had no suspected lesions or had a PI-RADS <3 lesion on MpMRI underwent TRUS-guided SPB (Group II). Pain assessment was performed using Visual Analog Scale (VAS) 5 min after the procedure. Following the procedure, the patients were asked to indicate the most painful biopsy step among the three steps (1: insertion of the probe into the rectum, 2: probe manipulation, 3: the piercing of the biopsy needle).

Study Design

Study Type:
Interventional
Actual Enrollment :
252 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
pain levels after standard transrectal prostate 12 core biopsy and MRI -US fusion prostate biopsy were detected and compared in 2 groups.pain levels after standard transrectal prostate 12 core biopsy and MRI -US fusion prostate biopsy were detected and compared in 2 groups.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Comparison of Pain Levels in Fusion Prostate Biopsy and Standard TRUS-Guided Biopsy
Actual Study Start Date :
Dec 1, 2016
Actual Primary Completion Date :
Jan 31, 2019
Actual Study Completion Date :
Feb 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group 1

In Group 1, Patients detected with a PI-RADS (Prostate Imaging Reporting and Data System) ≥3 lesion on MpMRI underwent MpMRI-guided MRI- US fusion prostate biopsy. In this fusion biopsy, 12 core standard biopsy and 2-4 cores of biopsies from lesions defined on multiparametric prostate MRI

Procedure: MRI- US fusion prostate biopsy (FPB)
FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
Other Names:
  • Group 1
  • Active Comparator: Group 2

    In Group 2, patients who had no suspected lesions or had a PI-RADS <3 lesion on MpMRI underwent Transrectal ultrasound guided 12 core prostate biopsy (SPB).

    Procedure: Standard transrectal 12 core biopsy
    TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
    Other Names:
  • Group 2
  • Outcome Measures

    Primary Outcome Measures

    1. To detect painful steps of biopsy procedure by asking patients verbally [Within 5 minutes after biopsy]

      to ask patients most painful step of procedure that verbally defined them before biopsy as 1: insertion of the probe into the rectum, 2: probe manipulation, and 3: the piercing of the biopsy needle

    2. Over all Visual analogue Score (VAS) score of procedure(From 0 to 100 points, 100 is max pain score according to patient) [Within 5 minutes after prostate biopsy]

      pain assessment was performed using Visual Analogue Scale (VAS)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 75 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Elevated blood prostate specific antigen (PSA) levels according to patients age. PSA

    2ng/ml for whom aged between 50-60, and PSA >4ng/ml for whom were above 60 years old

    • Having suspicious digital rectal examination

    • having multi-parametric prostate MRI before prostate biopsy

    • Having MRI defined lesions which were PIRADS - 3 -4-5

    Exclusion Criteria:
    • PSA > 50 ng/ml

    • previous negative biopsy

    • neurological disorders that could affect the pain level such as paraplegia or hemiplegia, analgesics use for any reason on the day of or the day before the procedure,

    • patients underwent biopsy under general anesthesia,

    • having such diseases as anal fissure or hemorrhoidal disease that could alter the pain threshold

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Urology, Ercieys University, Faculty Of Medicine, Kayseri Turkey 38039

    Sponsors and Collaborators

    • TC Erciyes University

    Investigators

    • Principal Investigator: Abdullah T Demirtaş, MD, Erciyes University Faculty of Medicine Department of Urolgoy

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Abdullah Demirtas, Abdullah Demirtas, Md, Assoc. Prof., TC Erciyes University
    ClinicalTrials.gov Identifier:
    NCT03859804
    Other Study ID Numbers:
    • 2014/508
    First Posted:
    Mar 1, 2019
    Last Update Posted:
    Mar 1, 2019
    Last Verified:
    Feb 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Abdullah Demirtas, Abdullah Demirtas, Md, Assoc. Prof., TC Erciyes University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 1, 2019